Article Text

Download PDFPDF
CP-071 Enzalutamide: experience in metastatic prostate cancer
  1. C Bonilla Galán1,
  2. D Briegas Morera2,
  3. LM Bravo Garcia-Cuevas2,
  4. C Meneses Mangas2,
  5. L Romero Soria2,
  6. S Martín Clavo2,
  7. R Medina Comas2,
  8. JF Rangel Mayoral2,
  9. J Liso Rubio2
  1. 1Hospital Infanta Cristina, Hospital Pharmacy, Badajoz, Spain
  2. 2Hospital Infanta Cristina, Hospital Pharmacy Service, Badajoz, Spain


Background Enzalutamide, an androgen receptor inhibitor administered orally, is approved for use in metastatic prostate cancer refractory to castration, when disease progresses during docetaxel treatment or after finishing it.

Purpose To describe the results of using enzalutamide in terms of effectiveness and safety.

Material and methods We conducted a retrospective study over eleven months (1/10/2014–30/09/2014), including every patient being treated with enzalutamide. Age, disease stage, previous treatment lines, enzalutamide start date and adverse effects were gathered from the patient’s clinical history and our Farmatools outpatient records module. In order to assess enzalutamide effectiveness, baseline and end-of-study prostatic specific antigen (PSA) levels were measured to calculate percentage PSA decrease; a response higher than 50% was considered positive.

Results We gathered data from five patients (average age 67.8 years, 80 maximum and 61 minimum), all diagnosed with stage IV (bone metastases) prostate cancer, refractory to chemical castration and docetaxel chemotherapy. Before starting, all of them received abiraterone (1 g, average treatment length 5.8 months). Average enzalutamide dose was 160 mg. Three patients experienced a PSA decrease of greater than 50% compared to baseline (95.2% maximum), while the remaining two dropped out of treatment because of ineffectiveness. Average length of enzalutamide treatment was 5 months. With regard to safety and adverse events, diarrhoea and asthenia were found in one patient, improving after a 25% dose reduction for 2.5 months, returning to the original dose after complete recovery.

Conclusion In this study, enzalutamide showed a response rate and safety profile similar to those observed in clinical trials and other available clinical evidence resources.

References and/or Acknowledgements No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.